Targeting TAM to Tame Pancreatic Cancer

Pancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl...

Full description

Saved in:
Bibliographic Details
Published in:Targeted oncology 2020-10, Vol.15 (5), p.579-588
Main Authors: von Itzstein, Mitchell S., Burke, Michael C., Brekken, Rolf A., Aguilera, Todd A., Zeh, Herbert J., Beg, Muhammad Shaalan
Format: Article
Language:English
Subjects:
Biomedicine
Medicine
Medicine & Public Health
Oncology
Review Article
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pancreatic cancer is expected to become the second leading cause of cancer-related death within the next few years. Current therapeutic strategies have limited effectiveness and therefore there is an urgency to develop novel effective therapies. The receptor tyrosine kinase subfamily TAM (Tyro3, Axl, MerTK) is directly implicated in the pathogenesis of the metastatic, chemoresistant, and immunosuppressive phenotype in pancreatic cancer. TAM inhibitors are promising investigational therapies for pancreatic cancer due to their potential to target multiple aspects of pancreatic cancer biology. Specifically, recent mechanistic investigations and therapeutic combinations in the preclinical setting suggest that TAM inhibition with chemotherapy, targeted therapy, and immunotherapy should be evaluated clinically.
ISSN:1776-2596
1776-260X
DOI:10.1007/s11523-020-00751-9